Reported Earnings • Jul 22
Second quarter 2026 earnings released: EPS: ₫1,384 (vs ₫793 in 2Q 2025) Second quarter 2026 results: EPS: ₫1,384 (up from ₫793 in 2Q 2025). Revenue: ₫519.2b (up 1.7% from 2Q 2025). Net income: ₫56.5b (up 105% from 2Q 2025). Profit margin: 11% (up from 5.4% in 2Q 2025). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 2% per year. Declared Dividend • Jul 03
Dividend of ₫2,500 announced Dividend of ₫2,500 is the same as last year. Ex-date: 14th September 2026 Payment date: 21st October 2026 Dividend yield will be 4.2%, which is higher than the industry average of 3.7%. Sustainability & Growth Dividend is covered by both earnings (56% earnings payout ratio) and cash flows (63% cash payout ratio). The dividend has increased by an average of 5.0% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 2.5% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • Apr 03
Full year 2025 earnings released: EPS: ₫4,856 (vs ₫4,962 in FY 2024) Full year 2025 results: EPS: ₫4,856. Revenue: ₫2.07t (up 8.8% from FY 2024). Net income: ₫198.4b (up 15% from FY 2024). Profit margin: 9.6% (in line with FY 2024). Announcement • Jan 15
Domesco Medical Import - Export Joint-Stock Corporation, Annual General Meeting, Apr 22, 2026 Domesco Medical Import - Export Joint-Stock Corporation, Annual General Meeting, Apr 22, 2026. Location: conference holl of domesco meclical import export, jsc, llo. 316 - ngulten hue street - m1t tra ward, dong thap province., Vietnam Reported Earnings • Oct 22
Third quarter 2025 earnings released: EPS: ₫683 (vs ₫802 in 3Q 2024) Third quarter 2025 results: EPS: ₫683 (down from ₫802 in 3Q 2024). Revenue: ₫528.9b (up 18% from 3Q 2024). Net income: ₫27.9b (down 15% from 3Q 2024). Profit margin: 5.3% (down from 7.3% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Upcoming Dividend • Sep 04
Upcoming dividend of ₫2,500 per share Eligible shareholders must have bought the stock before 11 September 2025. Payment date: 16 October 2025. Payout ratio is a comfortable 55% but the company is paying out more than the cash it is generating. Trailing yield: 3.9%. Lower than top quartile of Vietnamese dividend payers (7.4%). Lower than average of industry peers (5.0%). Reported Earnings • Jul 23
Second quarter 2025 earnings released: EPS: ₫776 (vs ₫1,162 in 2Q 2024) Second quarter 2025 results: EPS: ₫776 (down from ₫1,162 in 2Q 2024). Revenue: ₫510.3b (up 11% from 2Q 2024). Net income: ₫31.7b (down 4.5% from 2Q 2024). Profit margin: 6.2% (down from 7.2% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 7% per year, which means it is tracking significantly ahead of earnings growth. Declared Dividend • Jun 30
Dividend of ₫2,500 announced Dividend of ₫2,500 is the same as last year. Ex-date: 11th September 2025 Payment date: 16th October 2025 Dividend yield will be 4.0%, which is higher than the industry average of 3.7%. Sustainability & Growth Dividend is covered by earnings (57% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 6.1% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 37% to shift the payout ratio to a potentially unsustainable range, which is more than the 2.6% EPS decline seen over the last 5 years. Reported Earnings • Apr 27
First quarter 2025 earnings released: EPS: ₫1,151 (vs ₫1,179 in 1Q 2024) First quarter 2025 results: EPS: ₫1,151. Revenue: ₫469.1b (up 12% from 1Q 2024). Net income: ₫47.0b (up 15% from 1Q 2024). Profit margin: 10.0% (in line with 1Q 2024). Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₫55,200, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 16x in the Pharmaceuticals industry in Vietnam. Negligible returns to shareholders over past three years. New Risk • Mar 30
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 21% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 1.6% per year over the past 5 years. High level of non-cash earnings (21% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (6.2% average weekly change). Market cap is less than US$100m (₫2.36t market cap, or US$92.1m). New Risk • Feb 26
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₫2.54t (US$98.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.2% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (₫2.54t market cap, or US$98.9m). Valuation Update With 7 Day Price Move • Jan 28
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₫83,000, the stock trades at a trailing P/E ratio of 19.2x. Average trailing P/E is 18x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders of 76% over the past three years. New Risk • Jan 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Vietnamese stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.2% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (5.2% average weekly change). Announcement • Jan 22
Domesco Medical Import - Export Joint-Stock Corporation, Annual General Meeting, Apr 17, 2025 Domesco Medical Import - Export Joint-Stock Corporation, Annual General Meeting, Apr 17, 2025. Location: conference hall of domesco medical, import export jsc, no. 316, nguyen hue street, my phu ward, dong thap province., cao lanh Vietnam Reported Earnings • Oct 22
Third quarter 2024 earnings released: EPS: ₫802 (vs ₫1,092 in 3Q 2023) Third quarter 2024 results: EPS: ₫802 (down from ₫1,092 in 3Q 2023). Revenue: ₫448.1b (flat on 3Q 2023). Net income: ₫32.8b (down 27% from 3Q 2023). Profit margin: 7.3% (down from 10.0% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 4% per year. Upcoming Dividend • Sep 09
Upcoming dividend of ₫2,500 per share Eligible shareholders must have bought the stock before 13 September 2024. Payment date: 18 October 2024. Payout ratio is a comfortable 49% and the cash payout ratio is 89%. Trailing yield: 3.5%. Lower than top quartile of Vietnamese dividend payers (8.3%). Lower than average of industry peers (4.4%). Declared Dividend • Aug 26
Dividend of ₫2,500 announced Dividend of ₫2,500 is the same as last year. Ex-date: 13th September 2024 Payment date: 18th October 2024 Dividend yield will be 3.6%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by both earnings (51% earnings payout ratio) and cash flows (89% cash payout ratio). The dividend has increased by an average of 8.3% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 43% to shift the payout ratio to a potentially unsustainable range, which is more than the 2.8% EPS decline seen over the last 5 years. Reported Earnings • Jul 23
Second quarter 2024 earnings released: EPS: ₫1,500 (vs ₫1,011 in 2Q 2023) Second quarter 2024 results: EPS: ₫1,500 (up from ₫1,011 in 2Q 2023). Revenue: ₫461.7b (up 16% from 2Q 2023). Net income: ₫52.1b (up 80% from 2Q 2023). Profit margin: 11% (up from 7.2% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 11% per year. Buy Or Sell Opportunity • Jul 16
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 9.2% to ₫69,900. The fair value is estimated to be ₫57,777, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.2% over the last 3 years. Earnings per share has grown by 7.0%. Reported Earnings • Apr 25
First quarter 2024 earnings released: EPS: ₫1,003 (vs ₫951 in 1Q 2023) First quarter 2024 results: EPS: ₫1,003 (up from ₫951 in 1Q 2023). Revenue: ₫419.2b (up 3.4% from 1Q 2023). Net income: ₫41.0b (up 24% from 1Q 2023). Profit margin: 9.8% (up from 8.1% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 10% per year. Board Change • Apr 11
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Member of Supervisory Board Ergin Onur was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Mar 07
Domesco Medical Import - Export Joint-Stock Corporation, Annual General Meeting, Apr 23, 2024 Domesco Medical Import - Export Joint-Stock Corporation, Annual General Meeting, Apr 23, 2024. Announcement • Jan 12
Domesco Medical Import - Export Joint-Stock Corporation Announces Termination of an Giang Branch Domesco Medical Import - Export Joint-Stock Corporation announced that the Board of Directors approved to terminate operations of An Giang branch, information of branch as follows: The operation registration certfficate of branch was issued fo, the first time on March 27, 2015 as amended for 3rd time on April 06, 2023, branch's code: 1400460395-028, issued by Planning & Investment Department of An Giang Province. Address of the branch: No. 328, Ly Thai To Street, My Xuyen ward, long Xuyen city, An Giang province, Vietnam. Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: ₫1,092 (vs ₫1,415 in 3Q 2022) Third quarter 2023 results: EPS: ₫1,092 (down from ₫1,415 in 3Q 2022). Revenue: ₫444.9b (up 11% from 3Q 2022). Net income: ₫44.6b (down 9.2% from 3Q 2022). Profit margin: 10.0% (down from 12% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 6% per year. Announcement • Sep 19
Domesco Medical Import - Export Joint-Stock Corporation Announces Cash Dividend for the Year 2022, Payable on October 20, 2023 Domesco Medical Import - Export Joint-Stock Corporation announced cash dividend of 25.0% (2,500 dongs/share) for the year 2022. Ex-right date is September 21, 2023. Record date is September 22, 2023. The dividend will be payable on October 20, 2023. Upcoming Dividend • Sep 14
Upcoming dividend of ₫2,500 per share at 3.6% yield Eligible shareholders must have bought the stock before 21 September 2023. Payment date: 20 October 2023. Payout ratio is a comfortable 52% and this is well supported by cash flows. Trailing yield: 3.6%. Lower than top quartile of Vietnamese dividend payers (8.4%). Higher than average of industry peers (3.1%). Reported Earnings • Aug 20
Second quarter 2023 earnings released: EPS: ₫1,025 (vs ₫1,398 in 2Q 2022) Second quarter 2023 results: EPS: ₫1,025 (down from ₫1,398 in 2Q 2022). Revenue: ₫399.7b (flat on 2Q 2022). Net income: ₫35.6b (down 27% from 2Q 2022). Profit margin: 8.9% (down from 12% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has increased by 8% per year. Reported Earnings • Jul 22
Second quarter 2023 earnings released: EPS: ₫1,374 (vs ₫1,398 in 2Q 2022) Second quarter 2023 results: EPS: ₫1,374 (down from ₫1,398 in 2Q 2022). Revenue: ₫399.7b (flat on 2Q 2022). Net income: ₫47.7b (down 1.8% from 2Q 2022). Profit margin: 12% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 9% per year. Reported Earnings • Apr 09
Full year 2022 earnings released: EPS: ₫5,761 (vs ₫4,587 in FY 2021) Full year 2022 results: EPS: ₫5,761 (up from ₫4,587 in FY 2021). Revenue: ₫1.59t (up 6.3% from FY 2021). Net income: ₫200.1b (up 26% from FY 2021). Profit margin: 13% (up from 11% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 6% per year. Reported Earnings • Jan 28
Full year 2022 earnings released: EPS: ₫5,761 (vs ₫4,587 in FY 2021) Full year 2022 results: EPS: ₫5,761 (up from ₫4,587 in FY 2021). Revenue: ₫1.59t (up 6.3% from FY 2021). Net income: ₫200.1b (up 26% from FY 2021). Profit margin: 13% (up from 11% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings. Board Change • Nov 16
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 3 experienced directors. 3 highly experienced directors. No independent directors (5 non-independent directors). CEO, Vice Chairwoman, General Director & Member of Management Board Giang Thi Luong is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Reported Earnings • Oct 22
Third quarter 2022 earnings released: EPS: ₫1,415 (vs ₫1,118 in 3Q 2021) Third quarter 2022 results: EPS: ₫1,415 (up from ₫1,118 in 3Q 2021). Revenue: ₫399.4b (up 3.0% from 3Q 2021). Net income: ₫49.1b (up 27% from 3Q 2021). Profit margin: 12% (up from 10.0% in 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 9% per year whereas the company’s share price has fallen by 14% per year. Upcoming Dividend • Sep 07
Upcoming dividend of ₫2,500 per share Eligible shareholders must have bought the stock before 14 September 2022. Payment date: 19 October 2022. Payout ratio is a comfortable 50% and this is well supported by cash flows. Trailing yield: 4.9%. Lower than top quartile of Vietnamese dividend payers (7.5%). Higher than average of industry peers (3.7%). Announcement • Sep 01
Domesco Medical Import - Export Joint-Stock Corporation Announces Dividend for 2021, Payment Date Is October 19, 2022 Domesco Medical Import - Export Joint-Stock Corporation announced the dividend as follows: Exercise ratio: 25%/share (2,500 dongs/share). Payment date is October 19, 2022. Record date is September 15, 2022. Reported Earnings • Jul 21
Second quarter 2022 earnings released: EPS: ₫1,398 (vs ₫1,221 in 2Q 2021) Second quarter 2022 results: EPS: ₫1,398 (up from ₫1,221 in 2Q 2021). Revenue: ₫399.1b (up 9.8% from 2Q 2021). Net income: ₫48.6b (up 14% from 2Q 2021). Profit margin: 12% (in line with 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 10% per year. Board Change • Apr 27
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 3 experienced directors. 3 highly experienced directors. No independent directors (5 non-independent directors). CEO, Vice Chairwoman, General Director & Member of Management Board Giang Thi Luong is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Announcement • Apr 23
Domesco Medical Import - Export Joint-Stock Corporation Announces Proposal of Profit Distribution in 2021 Domesco Medical Import - Export Joint-Stock Corporation announced that to pay cash dividend for 2021 of 25.0% charter capital (cash payment). Buying Opportunity • Apr 20
Now 21% undervalued Over the last 90 days, the stock is up 16%. The fair value is estimated to be ₫77,287, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 11%. Reported Earnings • Apr 07
Full year 2021 earnings released: EPS: ₫4,587 (vs ₫4,653 in FY 2020) Full year 2021 results: EPS: ₫4,587 (down from ₫4,653 in FY 2020). Revenue: ₫1.50t (up 3.2% from FY 2020). Net income: ₫159.3b (down 1.4% from FY 2020). Profit margin: 11% (in line with FY 2020). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Announcement • Mar 31
Domesco Medical Import - Export Joint-Stock Corporation Announces Executive Changes Domesco Medical Import - Export Joint-Stock Corporation approved to terminate the labor contract with Mr. Nguyen Van Hoa according his resigning letter; BOD concurrently dismiss the position of Finance Deputy General Director of Mr. Nguyen Van Hoa. BOD authorize Mr. Nguyen Duy Tung - curuent CFO of the company - will be concurrently the authorized person to disclose information of the Comparry replace Mr. Nguyen Van Hoa. Reported Earnings • Jan 23
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: ₫4,588 (down from ₫5,170 in FY 2020). Revenue: ₫1.50t (up 3.2% from FY 2020). Net income: ₫159.3b (down 11% from FY 2020). Profit margin: 11% (down from 12% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 10% per year. Reported Earnings • Oct 21
Third quarter 2021 earnings released The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₫387.7b (up 17% from 3Q 2020). Net income: ₫38.8b (up 44% from 3Q 2020). Profit margin: 10.0% (up from 8.2% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year whereas the company’s share price has fallen by 7% per year. Upcoming Dividend • Oct 18
Upcoming dividend of ₫2,500 per share Eligible shareholders must have bought the stock before 25 October 2021. Payment date: 10 December 2021. Trailing yield: 4.1%. Lower than top quartile of Vietnamese dividend payers (6.2%). Higher than average of industry peers (3.5%). Valuation Update With 7 Day Price Move • Aug 30
Investor sentiment improved over the past week After last week's 15% share price gain to ₫60,600, the stock trades at a trailing P/E ratio of 14.2x. Average trailing P/E is 18x in the Pharmaceuticals industry in Vietnam. Total loss to shareholders of 18% over the past three years. Reported Earnings • Jul 22
Second quarter 2021 earnings released: EPS ₫1,221 (vs ₫1,883 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₫363.3b (down 6.3% from 2Q 2020). Net income: ₫42.4b (down 35% from 2Q 2020). Profit margin: 12% (down from 17% in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings. Reported Earnings • Apr 28
First quarter 2021 earnings released: EPS ₫684 (vs ₫1,228 in 1Q 2020) The company reported a poor first quarter result with weaker earnings and profit margins, although revenues were flat. First quarter 2021 results: Revenue: ₫290.3b (flat on 1Q 2020). Net income: ₫23.8b (down 44% from 1Q 2020). Profit margin: 8.2% (down from 15% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings. Reported Earnings • Jan 23
Full year 2020 earnings released: EPS ₫5,191 The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: ₫1.45t (down 1.1% from FY 2019). Net income: ₫180.3b (down 23% from FY 2019). Profit margin: 12% (down from 16% in FY 2019). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Jan 13
New 90-day high: ₫61,200 The company is up 10.0% from its price of ₫55,800 on 15 October 2020. The Vietnamese market is up 25% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. Announcement • Sep 18
Domesco Medical Import - Export Joint-Stock Corporation Approves to Dissolve its Thai Nguyen Branch The board of directors of Domesco Medical Import - Export Joint-Stock Corporation approved to dissolve its Thai Nguyen branch at Hung Vuong street, group 14, Trung Vuong Ward, Thai Nguyen Province Vietnam. 
